Indeed, resistance to BRAF/MEK inhibition has been observed in up to one-third of melanoma patients, with genetic analyses revealing most had acquired either activating mutations in additional MAPK pathway members or in compensatory signaling pathways [146,147]. Here, BRAF is linked to melanoma.